Extremecare

Phase 2Small molecule

IInstituto Brasileiro de Controle do Cancer

Extremecare is one of 8 small molecule programs targeting Hand-foot syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hand-Foot SyndromeActive, not recruiting

Hand-Foot SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Hand-Foot Syndrome

#DrugCompanyPhaseTrials

Celebrex

PPhiladelphia Eye Associates

Approved

—2

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 3

Zyloprim

Alnylam Pharmaceuticals

Phase 2

1 4

Nicorette

Pfizer

Phase 2

1 5

Alphagan

AbbVie

Phase 2

1 6

Doxorubicin HCL Liposome

AAccelerated Community Oncology Research Network

Phase 3

1 7

Sterile Urea

Pfizer

Preclinical

1 8

Extremecare

IInstituto Brasileiro de Controle do Cancer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hand-foot syndrome1 trial

Hydration Based on Thoitaine, Aloe Vera and Calendula, in the Prevention of Hand-Foot Syndrome in Patients Using Capecitabine

Unknown status·IInstituto Brasileiro de Controle do Cancer·Phase 2·NCT04833998·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Extremecare. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Extremecare compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Extremecare. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Instituto Brasileiro de Controle do Cancer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IInstituto Brasileiro de Controle do Cancer

Extremecare

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hand-foot syndrome1 trial

References

Drug Info

Quick Facts

Related News